Journal of the American Academy of Dermatology
Volume 60, Issue 1 , Pages 120-124 , January 2009

Treatment of intertriginous psoriasis: From the Medical Board of the National Psoriasis Foundation

  • Robert E. Kalb, MD

      Affiliations

    • Department of Dermatology, State University of New York School of Medicine and Biomedical Sciences, Buffalo, New York
    • ,
  • Jerry Bagel, MD

      Affiliations

    • College of Physicians and Surgeons of Columbia University, New York, New York
    • Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey
    • ,
  • Neil J. Korman, MD, PhD

      Affiliations

    • Murdough Family Center for Psoriasis, Case Western Reserve University/University Hospital of Cleveland, Cleveland, Ohio
    • ,
  • Mark G. Lebwohl, MD

      Affiliations

    • Department of Dermatology, Mount Sinai School of Medicine, New York, New York
    • ,
  • Melodie Young, MSN, RN, ANP

      Affiliations

    • Modern Dermatology, Dallas, Texas
    • ,
  • Elizabeth J. Horn, PhD, MBI

      Affiliations

    • National Psoriasis Foundation, Portland, Oregon
    • ,
  • Abby S. Van Voorhees, MD

      Affiliations

    • Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania
    • Corresponding Author InformationCorrespondence to: Abby S. Van Voorhees, MD, Hospital of the University of Pennsylvania, 2 Rhoads 3400 Spruce St, Philadelphia, PA 19104.
    • ,
  • National Psoriasis Foundation

References 

  1. Kerkhof PCM. Clinical features. In:  Kerkhof PCM editors. Textbook of psoriasis. Oxford: Blackwell Science Ltd; 1999;p. 3–29
  2. Farber EL, Nall MA. The natural history of psoriasis in 5600 patients. Dermatologica. 1974;148:1–18
  3. Berth-Jones J. Prescribing in psoriasis. Practitioner. 1994;238:231–234
  4. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ. 1999;318:593–596
  5. Kreuter A, Sommer A, Huyn J, Brautigam M, Brockmeyer NH, Altmeyer P, et al. 1% Pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis. Arch Dermatol. 2006;142:1138–1143
  6. Kienbaum S, Lehmann P, Ruzicka T. Topical calcipotriol in the treatment of intertriginous psoriasis. Br J Dermatol. 1996;135:647–650
  7. Dubweb GA, Eldebani S, Alhaddar J. Calcipotriol cream in the treatment of flexural psoriasis. Int J Tissue React. 2003;4:127–130
  8. Lebwohl M, Freeman AK, Chapman MS, Feldman SR, Hartel JE, Henning A, et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol. 2004;51:723–730
  9. Gribetz C, Ling M, Lebwohl M, Pariser D, Draelos Z, Gottlieb AB, et al. Tacrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol. 2004;51:731–738
  10. Freeman AK, Linowski GJ, Brady C, Lind L, VenVeldhuisen P, Singer G, et al. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol. 2003;48:564–568
  11. Ezquerra GM, Regana MS, Acosta EH, Millet PU. Topical tacrolimus for the treatment of psoriasis on the face, genitalia, intertriginous areas and corporal plaques. J Drugs Dermatol. 2006;5:334–343
  12. Brune A, Miller DW, Lin P, Cotrim-Russi D, Paller AS. Tacrolimus ointment is effective for psoriasis on the face and intertriginous areas in pediatric patients. Pediatr Dermatol. 2007;24:76–80
  13. Flystrom I, Bergbrant IM, Brared J, Brandberg LL. Microorganisms in intertriginous psoriasis: no evidence of Candida. Acta Derm Venereol. 2003;83:121–123
  14. Hughes J, Rustin MHA. Corticosteroids. In:  Kerkhof PCM editors. Textbook of psoriasis. Oxford: Blackwell Science Ltd; 1999;p. 148–159
  15. Lebwohl M, Tan M, Meador SL, Singer G. Limited application of fluticasone propionate ointment, 0.005% in patients with psoriasis of the face and intertriginous areas: analysis of safety and efficacy. J Am Acad Dermatol. 2001;44:77–82
  16. Bigby M. Pimecrolimus and tacrolimus for the treatment of intertriginous and facial psoriasis. Arch Dermatol. 2005;141:1152–1153
  17. Lebwohl M, Freeman AK, Chapman MS, Feldman SR, Hartel JE, Henning A, et al. Proven efficacy of tacrolimus for facial and intertriginous psoriasis. Arch Dermatol. 2005;141:1154
  18. Steele JA, Choi C, Kwong PC. Topical tacrolimus in the treatment of inverse psoriasis in children. J Am Acad Dermatol. 2005;53:713–716
  19. Noah PW. The role of microorganisms in psoriasis. Semin Dermatol. 1990;9:269–276
  20. Rosenberg EW, Noah PW, Skinner RB, Vanderzwaag R, West SJ, Browd JF, et al. Microbial associations of 167 patients with psoriasis. Acta Derm Venereol Suppl (Stockh). 1989;136(Suppl):72–75
  21. Nola I, Kostovic K, Kotrulja L, Lugovic L. The use of emollients as sophisticated therapy in dermatology. Acta Dermatovenereol Croat. 2003;11:80–87
  22. Jue SG, Dawson GW, Brozden RN. Ciclopirox olamine 1% cream: a preliminary review of its antimicrobial activity and therapeutic use. Drugs. 1985;29:330–341
  23. Farber EM, Nall ML. Perianal and intergluteal psoriasis. Cutis. 1992;50:336–338
  24. Carrascosa JM, Soria X, Domingo H, Ferrandiz C. Treatment of inverse psoriasis with excimer therapy and tacrolimus ointment. Dermatol Surg. 2007;33:361–363
  25. Mafong EA, Friedman PM, Kauvar AN, Bernstein LJ, Alexiades-Armenakas M, Geronemus RG. Treatment of inverse psoriasis with the 308 nm excimer laser. Dermatol Surg. 2002;28:530–532

 Supported by the National Psoriasis Foundation.

 Disclosure: Dr Kalb is a consultant and/or investigator for Amgen, Abbott, Astellas, Centocor, Genentech, and Warner-Chilcott and his practice provides phototherapy services. Dr Bagel is a clinical investigator for Centocor and a speaker for Amgen, Genentech, Abbott, Astellas, and Novartis, and his practice provides phototherapy services. Dr Korman is an investigator for or receives grant support from Abbott Laboratories, Amgen, Astellas, Biogen Idec, Centocor, Genentech, Genmab, Novartis, Peplin, and Seattle Genetics. He is also a speaker or consultant for Abbott Laboratories, Amgen, Genentech, Genmab, Novartis, and Peplin, and his practice provides phototherapy services. Dr Lebwohl is an investigator for Abbott Laboratories, Amgen, Astellas, Centocor, Connetics, Galderma, Genentech, 3M, Novartis, and Warner Chilcott. He is also a consultant for Abbott, Amgen, Astellas, BristolMyersSquibb, Centocor, Connetics, Galderma, Genentech, 3M, Novartis, Pfizer, and Warner Chilcott and speaker for Abbott, Amgen, Astellas, Centocor, Chester Valley, Connetics, Galderma, Genentech, 3M, Novartis, PharmaDerm, and Warner Chilcott, and his practice provides phototherapy services. Ms Young is a speaker for Abbott, Amgen, Connetics, and Genentech, an advisory board member for Abbott, Amgen, and Genentech, and her clinic provides phototherapy services. Dr Horn was an employee of the National Psoriasis Foundation. The National Psoriasis Foundation receives unrestricted funding from Abbott Immunology, Amgen and Wyeth, Astellas Pharma Inc, Barrier Therapeuics, Beiersdorf, Centocor, Daavlin, Galderma Laboratories, Genentech, National Biologic Corporation, Neutrogena, Photomedex, Stiefel Laboratories, and Warner Chilcott. Dr Van Voorhees has received grant support from Amgen, Astellas, and Warner Chilcott. She has been a consultant, advisory board member, or speaker for Abbott, Amgen, Centocor, Connetics, Genentech, and Warner Chilcott and a drug safety monitoring board member for Synta. She is a major stockholder in Merck. She provides phototherapy services as well.

 Reprints not available from the authors.

PII: S0190-9622(08)00807-4

doi: 10.1016/j.jaad.2008.06.041

Journal of the American Academy of Dermatology
Volume 60, Issue 1 , Pages 120-124 , January 2009

Article Tools

* Image Usage & Resolution